Journal of Neurophysiology
May 29, 2024
Adam T. Brockett, Nikolas A. Francis
8 citations
Recent studies have shown promising therapeutic potential for psychedelics in treating neuropsychiatric conditions. Musical experience during psilocybin-assisted therapy is predictive of treatment outcome, yet little is known about how psilocybin affects auditory processing. Here, we conducted two-photon imaging experiments in auditory cortex of awake mice that received a dose of psilocybin....
Religions
May 24, 2024
Jaime Clark-Soles
6 citations
The current psychedelic renaissance intersects with Christian practices in two key ways. First, as psychedelic-assisted therapy (PAT) becomes more common, Christians undergoing therapeutic medical treatment may seek outside support for integrating into their religious lives mystical experiences that occur during psychedelic sessions. Second, with increasing legal access to psychedelics, more...
May 23, 2024
Daniël Hoyer
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in depressed patients. Major depressive disorder comes with multiple endophenotypes; not surprisingly classical antidepressants (tricyclics, MAO inhibitors, SSRIs, SNRIs) are not universally effective. Most antidepressants target the 5-HT system,...
C&EN Global Enterprise
May 20, 2024
Sarah Braner
Reunion Neuroscience , a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk Foundation's investment arm Novo Holdings. The company's lead asset, RE104, is a novel psychedelic that is being developed to treat adjustment disorder in cancer patients as well as postpartum depression. RE104 is a prodrug of 4-OH-DiPT, which acts...
American Journal of Geriatric Psychiatry
May 19, 2024
Hannes Kettner, Leor Roseman, Adam Gazzaley et al.
18 citations
OBJECTIVE: Affective symptoms such as anxiety, low mood, and loneliness are prevalent and highly debilitating symptoms among older adults (OA). Serotonergic psychedelics are currently investigated as novel interventions for affective disorders, yet little is known regarding their effects in OA. We investigated the mental health effects and psychological mechanisms of guided psychedelic group...
iScience
May 19, 2024
Andres Ort, John W Smallridge, Erich Seifritz et al.
1 citation
Serotonergic psychedelics hold promise as a treatment modality for various psychiatric disorders and are currently applied in psychedelic-assisted psychotherapy. We investigated the learning effects of the serotonin receptor agonist psilocybin in a probabilistic cue-reward task with emotional cues in the form of neutral or fearful faces, presented either consciously or subconsciously. This...
Neuroethics
May 17, 2024
Chris Letheby
14 citations
Increasing evidence suggests that psychedelic experiences, undergone in controlled conditions, can have various durable psychological benefits. One such benefit is reductions in fear of death, which have been attested in both psychiatric patients and healthy people. This paper addresses the question: how, exactly, do psychedelic experiences reduce fear of death? It argues, against some...
May 11, 2024
Sachin R. Pendse, Neha Kumar, Munmun de Choudhury
6 citations
Psychedelic-assisted therapy has shown significant promise in alleviating treatment-resistant mental illness, prompting excitement among people with lived experience of mental illness. The emerging collective perception of psychedelics as tools for mental health has been dubbed the Pollan Effect. We investigate whether the Pollan Effect carries to online community discussions concerning...
Journal of Psychedelic Studies
May 10, 2024
Jarrett Robert Rose
3 citations
Revival, resurgence, renaissance-call it what you will, we are bearing witness to a second age of psychedelia in the West.It is well understood that the fruits borne of today's great scientific, therapeutic, and cultural advancements owe much to the seeds planted by the giants of the past.Yet when that past is discussed, the conversation is often dominated by the influence of only a select few...
ACS Medicinal Chemistry Letters
May 8, 2024
Robert B. Kargbo
2 citations
This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves...